The Effect of Xenical on Weight and Risk Factors
Launched by UNIVERSITY OF BRITISH COLUMBIA · Sep 7, 2005
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
Obesity is associated with numerous chronic diseases and increased cardiovascular mortality. It is also an independent risk factor for cardiovascular disease (CVD) in addition to being associated with diabetes and CVD risk factors. Weight loss interventions that target body fat reductions are associated with reductions in cholesterol levels, blood pressure and fasting glucose. Xenical (orlistat) is a gastrointestinal lipase inhibitor which results in a reduction in the absorption of exogenous fat. Studies of up to two years duration have demonstrated that those taking Xenical plus diet lost...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Body mass index ≥ 27 with one risk factor for cardiovascular disease OR overweight/obese individuals with type 2 diabetes on standard hypoglycemic agents
- • 2. Recently prescribed Xenical at the St. Paul's Hospital Lipid Clinic
- Exclusion Criteria:
- • 1. Patients with previous experience using Xenical
- • 2. Patients currently using other weight loss medications.
- • 3. Unable to provide informed consent.
- • 4. Less than 19 years of age
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Jiri Frohlich, MD
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials